RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), PRIME (European Union), Accelerated assessment (European Union)

Structure/Sequence

Sequence Code 9535613

Sequence Code 10051604

Sequence Code 10051610

Clinical Trials associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

NCT07467707

/ RecruitingPhase 3

A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)

Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities, and optimize the study parameters to local epidemiological conditions for CHIKV disease to overcome the challenges of assessing efficacy for CHIKV VLP vaccine.

Start Date26 May 2026

Sponsor / Collaborator

Bavarian Nordic A/S

[+4]

NCT07003984

/ RecruitingPhase 3

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 1 to <12 Years of Age

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to <12 years of age.

Start Date05 Jun 2025

Sponsor / Collaborator

Bavarian Nordic A/S

NCT06007183

/ Active, not recruitingPhase 3

A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (CHIKV VLP) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate CHIKV VLP booster vaccine induced serum neutralizing antibody (SNA) response at 3 or 4 years post-initial CHIKV VLP vaccination.

Start Date30 Aug 2023

Sponsor / Collaborator

Bavarian Nordic A/S

100 Clinical Results associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

100 Translational Medicine associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

100 Patents (Medical) associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

140

Literatures (Medical) associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

01 Aug 2026·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Perspectives on chikungunya vaccinology: from traditional platforms to epitope-driven rational design

Review

Author: Deng, Lei ; Sagheer, Usman

Chikungunya virus (CHIKV) is an arthritogenic alphavirus transmitted mainly by female Aedes aegypti and Aedes albopictus mosquitoes. It causes significant morbidity and persistent arthralgia, with its global spread driven by Aedes vectors and viral lineage diversification. Vaccination remains the most cost-effective prevention strategy, but development is hindered by unpredictable outbreaks, undefined immune correlates of protection, and the variability of immunodominant epitopes. This review analyzes CHIKV's genomic and proteomic features, mechanisms of viral entry and transmission, immune evasion strategies, and host immune responses to inform vaccine design. It also critically assesses major vaccine platforms and their limitations. For example, the licensed vaccines Ixchiq (live-attenuated) and Vimkunya (virus-like particle) still facing limitations regarding safety in specific populations, durability of cross-protection, manufacturing complexity, and global accessibility. The review then highlights emerging epitope-based strategies informed by immunoinformatics, which have identified conserved viral epitopes to guide rational multi-epitope vaccine designs. These approaches may address limitations of conventional platforms by precisely targeting conserved protective epitopes, broadening human leukocyte antigen coverage, and reducing reactogenicity. While most epitope-based CHIKV vaccine candidates remain in computational or early preclinical stages, continued integration of immunoinformatics, structural vaccinology, and experimental validation could accelerate the development of safer and more broadly protective next-generation CHIKV vaccines.

01 Aug 2026·VACCINE

Chikungunya virus virus-like particle vaccine (VIMKUNYA) elicits cross-neutralization across CHIKV lineages and against other alphaviruses after just one dose

Article

Author: Morello, Christopher S ; Stoddard, Steven T ; Warfield, Kelly L ; Tindale, Lauren C ; Burke, Crystal W ; Vang, Lo ; Brown, Nikia N ; Brown, Jennifer L ; Sandesara, Rohini G ; Gardner, Christina L

BACKGROUND:

Chikungunya virus (CHIKV) is a mosquito-borne virus that has spread widely and infected millions of people. CHIKV can cause both acute and chronic polyarthralgia that can be debilitating. The CHIKV virus-like particle (VLP) vaccine, VIMKUNYA™, is approved for use in the US, EU/EEA, UK, and Switzerland.

METHODS:

The aim of this study was two-fold: 1) determine if a single dose of CHIKV VLP vaccine generates cross-neutralizing antibodies against diverse CHIKV strains representing major viral lineages, as well as other arthritogenic alphaviruses, and 2) determine if previous alphavirus vaccination alters the ability to generate cross-neutralizing antibodies after CHIKV VLP vaccination. In this analysis, sera from participants enrolled in a phase 2 study were assessed for neutralizing activity against multiple CHIKV strains and related alphaviruses.

RESULTS:

A single vaccination with CHIKV VLP vaccine induced cross-neutralizing antibodies against multiple lineages of CHIKV and generated measurable cross-neutralizing activity against several related arthritogenic alphaviruses. Importantly, individuals with prior history of alphavirus vaccination exhibited immune responses comparable to alphavirus-naïve participants, indicating that earlier exposure did not hinder the ability to mount a strong CHIKV-specific or cross-reactive antibody response.

CONCLUSIONS:

These results highlight the broad immunogenic potential of CHIKV VLP vaccine and support its suitability across diverse populations, including individuals with prior alphavirus exposure, as previous vaccination did not diminish the ability to generate robust CHIKV-specific or cross-neutralizing antibody responses against CHIKV and other arthritogenic alphaviruses.

01 May 2026·Journal of Infection and Public Health

Chikungunya virus at a crossroads: Emergence, interventions, and global health strategies

Review

Author: Kam, Yiu-Wing ; Wu, Jiachen ; Wu, Shan

Chikungunya virus (CHIKV) has re-emerged as a major arboviral threat across 104 countries, situating nearly 2.8 billion people at risk. This review summarizes evidence on CHIKV epidemiology, molecular evolution, and public health challenges, with an emphasis on the observed expansion. Climate change, international travel, and the spread of Aedes vectors are driving the transmission of CHIKV into temperate regions, exemplified by the first large outbreak in Guangdong, China, in 2025. Adaptive viral mutations, waning population immunity, and urbanization are further accelerating epidemic growth. Although acute infections are often self-limiting, this review highlights the substantial burdens on low- and middle-income countries. Advances include two licensed vaccines (IXCHIQ and VIMKUNYA) and emerging point-of-care diagnostics; yet biomedical innovation alone remains insufficient. Thus, we also conclude that surveillance, vector control, risk mitigation, equity-focused policy, and coordinated global investment are essential to prevent the establishment of endemicity and its wider spread.

News (Medical) associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

15 Jul 2026

·www.biospace.com

Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) for Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older. The submission represents a key milestone in the partnership established between Bavarian Nordic and Eurofarma and marks an important step toward making the vaccine available in one of the countries most affected by chikungunya. Brazil accounts for a substantial proportion of reported chikungunya cases and related deaths globally, underscoring the continued need for effective preventive measures against the disease. Paul Chaplin, President & CEO of Bavarian Nordic , said: “The submission to Anvisa represents an important milestone in our strategy to expand access to our chikungunya vaccine beyond traditional travel markets and into regions where the disease poses a significant and recurring public health burden. Through our partnership with Eurofarma, we are combining global vaccine innovation with strong local expertise to support access for populations living at risk of chikungunya. We look forward to working closely with Eurofarma and Anvisa throughout the review process.” João Siffert, Vice President of Innovation at Eurofarma , said: “The introduction of the vaccine reinforces Eurofarma’s commitment to expanding public access to innovative healthcare products capable of addressing important public health challenges with efficacy and safety. Chikungunya continues to spread in Brazil and generates a significant impact on patients, not only during the acute infection but also through chronic effects, affecting both patients and healthcare systems. This vaccine uses a modern and widely validated technology, with a favorable safety pro the ability to induce a rapid immune response, contributing to strengthening disease prevention efforts.” About the partnership with Eurofarma In January 2026, Bavarian Nordic entered into an exclusive distribution agreement with Eurofarma covering Brazil. Under the agreement, Eurofarma is responsible for regulatory activities, commercialization, and distribution of the vaccine in the territory, while Bavarian Nordic remains the manufacturer and supplier of the product. Eurofarma also holds a right of first refusal for future opportunities in the broader Latin American region. About CHIKV VLP CHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization to prevent disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as one week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, supporting its use across a broad population. The vaccine has already been approved by the U.S. Food and Drug Administration (FDA), the European Commission, the UK Medicines and Healthcare products Regulatory Agency (MHRA), Swissmedic and Health Canada under the trade name VIMKUNYA ® . About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries 1 . Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years 2 . In 2025, more than 500,000 cases of chikungunya and nearly 200 associated deaths were reported worldwide 3 . More than half of the reported cases and associated deaths were reported from Brazil 4 . Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile 5 . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit . About Eurofarma Founded in 1972, Eurofarma covers key pharmaceutical segments and is the leader in medical prescriptions in Brazil. A Brazilian multinational company operating in 24 countries, with full coverage across Latin America and retail leadership in the region, the company also maintains operations in the United States and Africa, with more than 13,000 employees and 10 manufacturing facilities. In 2025, Eurofarma produced 630 million units. That same year, the company invested over USD 137 million in innovation projects and achieved net revenue exceeding USD 2.24 billion. For more information: . Contact investors: Europe: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com , Tel. +45 33 26 83 83 US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 1 World Health Organization (WHO). Chikungunya. 2 European Centre for Disease Prevention and Control. Chikungunya virus disease . . 3 World Health Organization (WHO). WHO Rapid Risk Assessment - Chikungunya virus disease, Global v.1 . . 4 Pan American Health Organization (PAHO). Chikungunya: analysis by country. 5 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

Drug ApprovalVaccine

02 Jul 2026

·www.biospace.com

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA ® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus infection for individuals 12 years of age and older. The single-dose vaccine is the first virus-like particle (VLP) vaccine approved in Canada for protection against the mosquito-borne chikungunya virus, expanding preventive options for travelers to endemic and outbreak regions. This marks the fifth regulatory approval of VIMKUNYA, which has also been approved by the U.S. Food and Drug Administration (FDA), the European Commission, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Swissmedic. Paul Chaplin, President and CEO of Bavarian Nordic , said: “Health Canada’s approval marks an important milestone in our efforts to expand access to our chikungunya vaccine globally. We are pleased to strengthen preventive options for Canadian travelers with a differentiated single-dose vaccine against a disease that can cause a significant and long-lasting burden.” About VIMKUNYA ® Chikungunya vaccine (recombinant, adsorbed) VIMKUNYA is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization to prevent disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as one week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, supporting its use across a broad population. About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries i . Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years ii . In 2025, more than 500,000 cases of chikungunya and nearly 200 associated deaths were reported worldwide iii . Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile iv . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit . Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com , Tel. +45 33 26 83 83 US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com i World Health Organization (WHO). Chikungunya. ii European Centre for Disease Prevention and Control. Chikungunya virus disease . . iii World Health Organization (WHO). WHO Rapid Risk Assessment - Chikungunya virus disease, Global v.1 . . iv Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Drug ApprovalVaccine

13 May 2026

·www.biospace.com

Bavarian Nordic Announces Interim Results for the First Three Months of 2026

COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026. Revenue for the first three months was DKK 1,058 million, comprised of: DKK 721 million from Travel Health, an increase of 14% compared to the first quarter of 2025 when adjusting for discontinued partnership revenue. The growth was primarily driven by increased demand for rabies vaccines and the continued launch of the chikungunya vaccine. DKK 294 million from Public Preparedness, a decrease of 53% compared to the first quarter of 2025, which is in line with expectations as 2026 is expected to be a normalized year for this business without material impact from mpox outbreaks. DKK 44 million in other revenue. The operating profit (EBITDA) was DKK 165 million, corresponding to an EBITDA margin of 16%. The financial guidance for the full year, which was upgraded on May 11, is maintained at a revenue of DKK 5,500 - 5,700 million and an EBITDA margin of approximately 28%. DKK million Q1 2026 Q1 2025 FY 2026 Guidance Current FY 2026 Guidance Original Revenue 1,058 1,347 5,500 – 5,700 5,000 – 5,200 EBITDA margin 16% 31% ~28% ~25% Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “Our Travel Health business continues the strong performance, delivering a 14% growth year-over-year, when adjusting for the discontinued partnerships. This underlines our solid focus on organic growth in existing markets, in particular driven by our rabies vaccine, but also by the continued launch of the chikungunya vaccine across new markets. This year, we have launched our vaccine in the Benelux countries, which will be fully onboarded by mid-2026, where also Switzerland will get access to our vaccine after the recent approval by Swissmedic. We also made important advances in our access strategy for the chikungunya vaccine through strategic partnerships in India and Brazil. In our Public Preparedness business, we keep advancing our mpox/smallpox vaccine program and have recently submitted data to EMA to support extension of the approval for children 2-11 years later this year. With our recent contract award from the U.S. government and a broadened customer base, we are well on track to deliver revenue above the communicated base level of DKK 1.5 to 2 billion from this business, despite no expected material impact from outbreaks.” Highlights from the first quarter In January, Bavarian Nordic launched the first tranche of a planned share buy-back program for up to DKK 500 million during 2026. The first tranche comprised a buy-back of shares for up to DKK 150 million and was completed in February. The second tranche of DKK 200 million was initiated in March. The shares will be held as treasury stock for the purpose of adjusting the capital structure. In January, Bavarian Nordic entered into an agreement with Eurofarma, granting them exclusive rights to sell and distribute the Company’s chikungunya vaccine in Brazil. Eurofarma was also granted the right of first refusal for any future opportunity to register and commercialize the chikungunya vaccine in the rest of Latin America. In February, Bavarian Nordic announced a new order valued at USD 22.5 million from the Public Health Agency of Canada for the Company’s mpox and smallpox vaccine. In March, Bavarian Nordic announced that the Board of Directors had entered into an agreement with CEO, Paul Chaplin, who will step down. Paul Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. In March, Bavarian Nordic announced an expansion of the strategic partnership with Serum Institute of India (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries. In March, Bavarian Nordic submitted clinical data to the European Medicines Agency (EMA) to support the extension of the MVA-BN ® mpox and smallpox vaccine indication to include children aged 2 to 11 years. If successful, approval could be obtained later in 2026. Events after the reporting date In April, the Swiss Agency for Therapeutic Products, Swissmedic, approved Vimkunya ® for the prevention of disease caused by chikungunya virus in individuals aged 12 years and above. Bavarian Nordic expects to launch the vaccine in Switzerland in the second quarter of 2026. In May, Bavarian Nordic completed the second tranche of the planned share buy-back program for 2026. The second tranche comprised a buy-back of shares for DKK 200 million, and, combined with the first tranche, shares of a total aggregate amount of approximately DKK 350 million have now been repurchased during 2026. In May, Bavarian Nordic was awarded additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS ® smallpox vaccine to the U.S. Government. The options will support the manufacturing and supply of freeze-dried JYNNEOS, including manufacturing of additional bulk vaccine necessary for fulfilling the contract. Following this order, the full-year guidance for 2026 was upgraded. Conference call and webcast The management of Bavarian Nordic will host an investor/analyst call today at 2 pm CEST (8 am EDT) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via . To join the Q&A session, please register in advance via . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 Company Announcement no. 24 / 2026 Attachments Bavarian Nordic Q1 2026 Report Bavarian Nordic Announces Interim Results for the First Three Months of 2026

VaccineDrug ApprovalFinancial StatementExecutive Change

100 Deals associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chikungunya Fever	United States	Bavarian Nordic A/S	14 Feb 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACR2025	Phase 2/3	Chikungunya Fever	3,141	CHIKV VLP vaccine	ymjjeafxpa(svoneyesnb) = uclkwaujtw yncgixdegw (iebrvniukk ) View more	Positive	24 Oct 2025
				Placebo	fxwajyqanx(eqqyiawkxw) = xlebkvisbj mdixnivyzx (icztqhpkkb )
NCT03992872 (Pubmed \| Lancet Microbe)	Phase 2	Alphavirus Infections	60	Previous alphavirus vaccine recipients	vbwqiryhbo(kddrshffet) = There was no statistically significant difference in the incidence of solicited adverse events between the previous alphavirus vaccine recipients and alphavirus vaccine-naive controls (53.3% vs 40.0%, respectively), although the relatively small sample size of the trial limited the power to detect a significant difference, and there were no reported vaccine-related serious adverse events rjtrtkbxnb (xywdoegxmu )	Positive	01 Apr 2025
				Alphavirus vaccine-naive controls
NCT05349617 (FDA_CBER) Manual	Phase 3	Chikungunya Fever	-	VIMKUNYA	auirxjcstz(pyhcqfbrqa) = ffjupvfxfs kycvmwfwzo (svyjzyffhq, 582.3 - 892.7) View more	Positive	14 Feb 2025
				Placebo	auirxjcstz(pyhcqfbrqa) = bzsumpmkep kycvmwfwzo (svyjzyffhq, 6.5 - 10.0) View more
NCT05072080 (FDA_CBER) Manual	Phase 3	Chikungunya Fever	-	VIMKUNYA	fhsguagtxo(yhuzfqjcgi) = dsiirztaka dygshkkcrm (dtjolxuijj, 1504.1 - 1695.6) View more	Positive	14 Feb 2025
				Placebo	fhsguagtxo(yhuzfqjcgi) = cbmklcpysg dygshkkcrm (dtjolxuijj, 7.0 - 8.8) View more
NCT05349617 (CTgov)	Phase 3	-	413	CHIKV VLP/adjuvant (Group 1 - PXVX0317)	cibsfriyuc = hfsonjazxd xmuevskdug (dmejagwtoa, mbfvtkyjox - cppnrmvxxl) View more	-	13 Dec 2024
				Placebo (Group 2 - Placebo)	cibsfriyuc = rzwkjjlrci xmuevskdug (dmejagwtoa, yknwvsngoz - oquysaxfnk) View more
NCT05072080 (CTgov)	Phase 3	Chikungunya Fever	3,258	CHIKV VLP/adjuvant (Group 1)	kmdebkmypn = wkoivjuwlx jldgtxyyln (fkzmglizhs, ggaveiihcs - aqdbfofwtc) View more	-	30 Aug 2024
				CHIKV VLP/adjuvant (Group 2)	kmdebkmypn = izrfzhfwzt jldgtxyyln (fkzmglizhs, dwsxhqrfsl - fbqlduuciv) View more
NCT02562482 (phase 2, Pubmed \| Vaccine)	Phase 2	Chikungunya Fever focus reduction neutralizing antibody	400	CHIKV VLP vaccine seropositive recipients	nlqceabeku(lekutfelfp) = gjpyijcxdy iwfyoazxwv (qalcdyvtbk )	Positive	01 Oct 2023
				CHIKV VLP vaccine seronegative recipients	nlqceabeku(lekutfelfp) = zfgfggyurv iwfyoazxwv (qalcdyvtbk )
NCT05065983 (CHIKV VLP, CTgov)	Phase 2	Chikungunya Fever	25	CHIKV VLP, adjuvanted	ffsktcpocs = pyakusxwni omzfsqfrev (buogdmwmjc, yxszwdszsz - dwdwapsuga) View more	-	28 Feb 2023
NCT03992872 (WRAIR, Biospace) Manual	Phase 2	Alphavirus Infections \| Chikungunya Fever	60	PXVX 0317	gitpaekcbr(shknuuhutd) = The study demonstrated that the CHIKV VLP vaccine candidate was well-tolerated and immunogenic in both alphavirus vaccine-naïve participants and participants previously vaccinated against the Venezuelan equine encephalitis virus. oiypsobwrc (qikpopjohy )	Positive	01 Nov 2022
NCT02562482 (Pubmed \| J Coll Physicians Surg Pak) Manual	Phase 2	Chikungunya Fever	400	PXVX-0317	cbzftvbqrm(mkwurajwjl) = mtkhfznegg esywnovgkj (wknvlrvonv ) View more	Positive	14 Apr 2020
				Placebo	cbzftvbqrm(mkwurajwjl) = aqltjalknr esywnovgkj (wknvlrvonv ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis